In the treatment of epilepsy there are constantly new drugs being developed to help patients manage their seizures. In the recent past there have been four new medications, each with their own benefits but also with their own risks as well.
Latest Epilepsy Medications
Share
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New York, NY, US) discusses the needs of adults with focal epilepsy and the mechanisms of action of XEN1101, a novel, potent, selective Kv7.2/7.3 potassium channel. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The randomized, double-blind, placebo-controlled phase IIb study X-TOLE (NCT03796962) is investigating the efficacy of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy.  In this interview with touchNEUROLOGY, Prof. Jacqueline French (Comprehensive Epilepsy Center, New York University, New ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
Mark CompleteCompleted
BookmarkBookmarked
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. The impact and the constant care required for someone living with DS has on the patient and their family's quality of life can be huge. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Dravet Syndrome (DS) is a rare neurological condition, beginning in infancy and lasting a lifetime. touchNEUROLOGY were joined by Galia Wilson, Chair and Trustee of Dravet Syndrome UK (DSUK), a charity created in 2008 by a group of parents who came ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The International League Against Epilepsy (ILAE) was founded in 1909 and is an organisation of more than 120 national chapters. It is an association of health care professionals and scientists working toward a world where no person's life is limited by epilepsy. ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
touchNEUROLOGY caught up with the INS President, Prof. Marc Russo, to discuss the upcoming congress and what to expect. The International Neuromodulation Society (INS) is excited to announce the relaunch of the in-person INS 15th World Congress in Barcelona, Spain, ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
The efficacy and safety of fenfluramine, an anti-seizure medication, in patients with Lennox-Gastaut syndrome was assessed in phase 3 and open label extension studies (NCT03355209). Dr Kelly Knupp (Children’s Hospital Colorado, University of Colorado, CO, USA) discusses the findings of ...
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
NEW
Cenobamate is approved in the United States for focal-onset seizures (partial-onset seizures) in adults both as adjunctive and monotherapy. In the EU, cenobamate is approved as adjunctive therapy for focal-onset seizures with or without secondary generalization for adult patients who ...
Mark CompleteCompleted
BookmarkBookmarked
The World Congress on Controversies in Neurology (CONy) provides a platform for international experts to discuss and compare experience in many areas of neurology and in treatment of neurological diseases, thus closing the gap between the expansion of knowledge and ...
Mark CompleteCompleted
BookmarkBookmarked
touchNEUROLOGY met with Professor Mary Koenig (McGovern Medical School, UTHealth, Houston, TX, USA) to discuss the efficacy and safety findings from the phase 2 clinical study investigating oral ganaxolone for the treatment of tuberous sclerosis complex (NCT04285346). The abstract 'Phase 2 Open-label ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
